Arrivent Biopharma Inc (AVBP)

$22.29 -0.03 (-0.13%)
Market Cap 921.39M
Revenue (ttm) 0.00
Net Income (ttm) -80.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 77,000
Avg Vol 373,300
Day's Range N/A - N/A
Shares Out 41.28M
Stochastic %K 34%
Beta 0.95
Analysts Strong Sell
Price Target $40.75

Company Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment o...

Industry: Biotechnology
Sector: Healthcare
Phone: 628 277 4836
Address:
18 Campus Boulevard, Suite 100, Newtown Square, United States
JarvisFlow
JarvisFlow Dec. 23 at 12:56 PM
Cantor Fitzgerald updates rating for ArriVent BioPharma ( $AVBP ) to Overweight.
0 · Reply
notreload_ai
notreload_ai Dec. 23 at 10:57 AM
Cantor Fitzgerald initiates coverage on $AVBP with an Overweight rating, highlighting strong Phase 3 potential and significant upside. https://notreload.xyz/cantor-fitzgerald-starts-coverage-on-arrivent-biopharma-with-strong-upside/
0 · Reply
prismmarketview
prismmarketview Dec. 22 at 4:03 PM
ArriVent BioPharma (Nasdaq: $AVBP) has dosed the first patient in its global Phase 3 ALPACCA trial evaluating firmonertinib as a first-line, chemo-free treatment for EGFR PACC mutant NSCLC—an underserved population with limited targeted options. https://prismmarketview.com/arrivent-doses-first-patient-in-pivotal-phase-3-alpacca-trial-for-egfr-pacc-mutant-lung-cancer/
0 · Reply
UgoGreg
UgoGreg Dec. 20 at 6:02 PM
$AVBP https://youtu.be/ygBN8MilTyc
0 · Reply
justiceforb_85
justiceforb_85 Dec. 18 at 4:36 AM
$AVBP looking forward to P3 result for 1L exon 20 NSCLC early next year.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 12:33 PM
BTIG updates rating for ArriVent BioPharma ( $AVBP ) to Buy, target set at 45.
0 · Reply
justiceforb_85
justiceforb_85 Dec. 4 at 2:09 AM
$BDTX over-reaction as I think silevertinib will have a place in 1L non-classical mutations with the exception of PACC where $AVBP will be the leader. Main concern is whether BP will partner with (or buy outright) the company to run a P3 for non-classical NSCLC.
1 · Reply
SuperGreenToday
SuperGreenToday Dec. 4 at 12:33 AM
$AVBP Share Price: $22.93 Contract Selected: Jul 17, 2026 $20 Calls Buy Zone: $5.95 – $7.35 Target Zone: $10.56 – $12.90 Potential Upside: 68% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RunnerSignals
RunnerSignals Nov. 26 at 9:44 PM
$AVB $AVBP $AXS $BAER $BBOT showing massive upside! and these tickers aren’t shy https://stocksrunner.com/news/2025-11-26-stock-upgrades-today-see-wall-street-boost-confidence
0 · Reply
JarvisFlow
JarvisFlow Nov. 25 at 6:02 PM
Truist Securities has updated their rating for ArriVent BioPharma ( $AVBP ) to Buy with a price target of 43.
0 · Reply
Latest News on AVBP
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts

Dec 25, 2025, 8:30 AM EST - 3 hours ago

ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Dec 22, 2025, 8:00 AM EST - 3 days ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 8:00 AM EST - 6 weeks ago

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Sep 22, 2025, 4:05 PM EDT - 3 months ago

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Sep 9, 2025, 8:00 AM EDT - 3 months ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 8:00 AM EDT - 4 months ago

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Jul 21, 2025, 8:00 AM EDT - 5 months ago

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Jul 2, 2025, 8:22 AM EDT - 6 months ago

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

BV CNC

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 11:15 PM EDT - 6 months ago

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 4:05 PM EDT - 6 months ago

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

Jun 23, 2025, 7:00 AM EDT - 6 months ago

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Jun 20, 2025, 4:05 PM EDT - 6 months ago

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

ArriVent BioPharma Reports First Quarter 2025 Financial Results

May 12, 2025, 8:00 AM EDT - 8 months ago

ArriVent BioPharma Reports First Quarter 2025 Financial Results

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Apr 28, 2025, 8:00 AM EDT - 8 months ago

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

ArriVent BioPharma Reports Full Year 2024 Financial Results

Mar 3, 2025, 7:00 AM EST - 10 months ago

ArriVent BioPharma Reports Full Year 2024 Financial Results

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Jan 21, 2025, 7:00 PM EST - 1 year ago

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Sep 9, 2024, 12:05 PM EDT - 1 year ago

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

Aug 15, 2024, 7:01 AM EDT - 1 year ago

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:01 PM EDT - 1 year ago

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

Aug 12, 2024, 8:00 AM EDT - 1 year ago

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

Jun 5, 2024, 7:00 AM EDT - 1 year ago

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 16, 2024, 4:05 PM EDT - 1 year ago

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

ArriVent BioPharma Reports First Quarter 2024 Financial Results

May 8, 2024, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports First Quarter 2024 Financial Results

ArriVent Appoints Kristine Peterson to its Board of Directors

Apr 22, 2024, 4:05 PM EDT - 1 year ago

ArriVent Appoints Kristine Peterson to its Board of Directors

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Mar 28, 2024, 8:30 PM EDT - 1 year ago

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

ArriVent BioPharma Reports Full Year 2023 Financial Results

Mar 28, 2024, 4:05 PM EDT - 1 year ago

ArriVent BioPharma Reports Full Year 2023 Financial Results

ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment

Jan 29, 2024, 6:15 PM EST - 2 years ago

ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment

JarvisFlow
JarvisFlow Dec. 23 at 12:56 PM
Cantor Fitzgerald updates rating for ArriVent BioPharma ( $AVBP ) to Overweight.
0 · Reply
notreload_ai
notreload_ai Dec. 23 at 10:57 AM
Cantor Fitzgerald initiates coverage on $AVBP with an Overweight rating, highlighting strong Phase 3 potential and significant upside. https://notreload.xyz/cantor-fitzgerald-starts-coverage-on-arrivent-biopharma-with-strong-upside/
0 · Reply
prismmarketview
prismmarketview Dec. 22 at 4:03 PM
ArriVent BioPharma (Nasdaq: $AVBP) has dosed the first patient in its global Phase 3 ALPACCA trial evaluating firmonertinib as a first-line, chemo-free treatment for EGFR PACC mutant NSCLC—an underserved population with limited targeted options. https://prismmarketview.com/arrivent-doses-first-patient-in-pivotal-phase-3-alpacca-trial-for-egfr-pacc-mutant-lung-cancer/
0 · Reply
UgoGreg
UgoGreg Dec. 20 at 6:02 PM
$AVBP https://youtu.be/ygBN8MilTyc
0 · Reply
justiceforb_85
justiceforb_85 Dec. 18 at 4:36 AM
$AVBP looking forward to P3 result for 1L exon 20 NSCLC early next year.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 12:33 PM
BTIG updates rating for ArriVent BioPharma ( $AVBP ) to Buy, target set at 45.
0 · Reply
justiceforb_85
justiceforb_85 Dec. 4 at 2:09 AM
$BDTX over-reaction as I think silevertinib will have a place in 1L non-classical mutations with the exception of PACC where $AVBP will be the leader. Main concern is whether BP will partner with (or buy outright) the company to run a P3 for non-classical NSCLC.
1 · Reply
SuperGreenToday
SuperGreenToday Dec. 4 at 12:33 AM
$AVBP Share Price: $22.93 Contract Selected: Jul 17, 2026 $20 Calls Buy Zone: $5.95 – $7.35 Target Zone: $10.56 – $12.90 Potential Upside: 68% ROI Time to Expiration: 225 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RunnerSignals
RunnerSignals Nov. 26 at 9:44 PM
$AVB $AVBP $AXS $BAER $BBOT showing massive upside! and these tickers aren’t shy https://stocksrunner.com/news/2025-11-26-stock-upgrades-today-see-wall-street-boost-confidence
0 · Reply
JarvisFlow
JarvisFlow Nov. 25 at 6:02 PM
Truist Securities has updated their rating for ArriVent BioPharma ( $AVBP ) to Buy with a price target of 43.
0 · Reply
Blaze27
Blaze27 Nov. 16 at 9:13 PM
$AVBP
0 · Reply
laaarsas
laaarsas Nov. 16 at 8:30 PM
$AVBP what is vibe like in here?
0 · Reply
itsphd
itsphd Nov. 14 at 8:19 PM
$AVBP Big buyer coming into the option market for no apparent reason out some 5 months. Curious Took 200 shares at 20.77
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 8:34 PM
Citigroup updates rating for ArriVent BioPharma ( $AVBP ) to Buy, target set at 33 → 31.
0 · Reply
ADMAGuy
ADMAGuy Sep. 23 at 3:09 PM
$AUTL So Brent Rice Joins $AVBP as Chief Commercial Officer today. Thats good riddance from Dr. Itin.
3 · Reply
Bigeyes2
Bigeyes2 Sep. 6 at 10:19 PM
$AVBP Cup and handle
0 · Reply
ProfitCraft
ProfitCraft Aug. 23 at 6:24 AM
$AVBP Armor Bio Partners is a blank check company seeking life sciences acquisition target
0 · Reply
Scarlett2228
Scarlett2228 Aug. 12 at 7:49 PM
$AVBP adding
0 · Reply
JarvisFlow
JarvisFlow Aug. 12 at 12:30 PM
HC Wainwright & Co. has updated their rating for ArriVent BioPharma ( $AVBP ) to Buy with a price target of 42.
0 · Reply
JarvisFlow
JarvisFlow Aug. 12 at 12:00 PM
Citigroup has adjusted their stance on ArriVent BioPharma ( $AVBP ), setting the rating to Buy with a target price of 40 → 33.
0 · Reply
JarvisFlow
JarvisFlow Jul. 22 at 10:30 AM
HC Wainwright & Co. has adjusted their stance on ArriVent BioPharma ( $AVBP ), setting the rating to Buy with a target price of 40.
0 · Reply
JarvisFlow
JarvisFlow Jul. 10 at 6:15 PM
Goldman Sachs updates rating for ArriVent BioPharma ( $AVBP ) to Buy, target set at 33.
0 · Reply